tradingkey.logo

Pacific Biosciences of California Inc

PACB
1.820USD
+0.105+6.12%
Close 02/06, 16:00ETQuotes delayed by 15 min
549.37MMarket Cap
LossP/E TTM

Pacific Biosciences of California Inc

1.820
+0.105+6.12%

More Details of Pacific Biosciences of California Inc Company

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Pacific Biosciences of California Inc Info

Ticker SymbolPACB
Company namePacific Biosciences of California Inc
IPO dateOct 27, 2010
CEOHenry (Christian O)
Number of employees575
Security typeOrdinary Share
Fiscal year-endOct 27
Address1305 O'brien Drive
CityMENLO PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94025
Phone16505218000
Websitehttps://www.pacb.com/
Ticker SymbolPACB
IPO dateOct 27, 2010
CEOHenry (Christian O)

Company Executives of Pacific Biosciences of California Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
696.81K
-152571.00%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
110.00K
-22821.00%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
110.00K
-22821.00%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
+22821.00%
Mr. Bill Ericson ,J.D.
Mr. Bill Ericson ,J.D.
Independent Director
Independent Director
--
--
Dr. Lucy Shapiro, Ph.D.
Dr. Lucy Shapiro, Ph.D.
Independent Director
Independent Director
--
-22821.00%
Ms. Kathy P. Ordonez
Ms. Kathy P. Ordonez
Independent Director
Independent Director
--
--
Mr. Mark Van Oene
Mr. Mark Van Oene
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Hannah A. Valantine, M.D.
Dr. Hannah A. Valantine, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Smith
Mr. Christopher M. (Chris) Smith
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
696.81K
-152571.00%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
110.00K
-22821.00%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
110.00K
-22821.00%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
+22821.00%
Mr. Bill Ericson ,J.D.
Mr. Bill Ericson ,J.D.
Independent Director
Independent Director
--
--
Dr. Lucy Shapiro, Ph.D.
Dr. Lucy Shapiro, Ph.D.
Independent Director
Independent Director
--
-22821.00%

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Consumable revenue
21.28M
55.35%
Instrument revenue
11.32M
29.44%
Service And Other
5.84M
15.20%
By RegionUSD
Name
Revenue
Proportion
North America
18.10M
47.08%
Europe (including the Middle East and Africa)
10.75M
27.97%
Asia Pacific
9.59M
24.95%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumable revenue
21.28M
55.35%
Instrument revenue
11.32M
29.44%
Service And Other
5.84M
15.20%

Shareholding Stats

Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
12.34%
SoftBank Group Corp
6.77%
BlackRock Institutional Trust Company, N.A.
6.58%
The Vanguard Group, Inc.
5.64%
Edmond de Rothschild Asset Management (France) S.A.
3.54%
Other
65.12%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
12.34%
SoftBank Group Corp
6.77%
BlackRock Institutional Trust Company, N.A.
6.58%
The Vanguard Group, Inc.
5.64%
Edmond de Rothschild Asset Management (France) S.A.
3.54%
Other
65.12%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.49%
Investment Advisor/Hedge Fund
10.60%
Holding Company
6.77%
Hedge Fund
3.14%
Individual Investor
1.16%
Corporation
1.16%
Research Firm
1.13%
Sovereign Wealth Fund
0.40%
Bank and Trust
0.14%
Other
35.01%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
547
169.14M
56.02%
-65.44M
2025Q3
566
166.98M
55.32%
-97.69M
2025Q2
600
214.62M
71.52%
-110.62M
2025Q1
629
227.30M
75.82%
-104.21M
2024Q4
625
258.31M
94.32%
-61.55M
2024Q3
618
231.32M
84.94%
-85.30M
2024Q2
629
240.26M
88.29%
-64.03M
2024Q1
637
265.38M
97.57%
-38.04M
2023Q4
643
276.71M
103.53%
-9.49M
2023Q3
631
258.82M
103.48%
-18.47M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
30.92M
10.24%
-5.37M
-14.81%
Sep 30, 2025
SoftBank Group Corp
20.45M
6.77%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
19.86M
6.58%
-103.12K
-0.52%
Sep 30, 2025
The Vanguard Group, Inc.
16.38M
5.43%
+362.80K
+2.27%
Sep 30, 2025
Edmond de Rothschild Asset Management (France) S.A.
10.68M
3.54%
-2.69M
-20.13%
Sep 30, 2025
Amova Asset Management Co., Ltd.
8.68M
2.87%
-540.90K
-5.87%
Sep 30, 2025
Geode Capital Management, L.L.C.
6.91M
2.29%
+187.78K
+2.79%
Sep 30, 2025
State Street Investment Management (US)
5.91M
1.96%
+155.06K
+2.69%
Sep 30, 2025
Madrone Advisors, LLC
4.98M
1.65%
-11.79M
-70.31%
Sep 30, 2025
Millennium Management LLC
4.92M
1.63%
+4.05M
+466.29%
Sep 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
2.3%
iShares Genomics Immunology and Healthcare ETF
1.31%
Invesco NASDAQ Future Gen 200 ETF
0.96%
Global X Genomics & Biotechnology ETF
0.69%
ARK Innovation ETF
0.58%
AXS Green Alpha ETF
0.58%
WisdomTree BioRevolution Fund
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.07%
View more
ARK Genomic Revolution ETF
Proportion2.3%
iShares Genomics Immunology and Healthcare ETF
Proportion1.31%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.96%
Global X Genomics & Biotechnology ETF
Proportion0.69%
ARK Innovation ETF
Proportion0.58%
AXS Green Alpha ETF
Proportion0.58%
WisdomTree BioRevolution Fund
Proportion0.48%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.09%
ProShares Ultra Nasdaq Biotechnology
Proportion0.08%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI